Supriya Lifescience Limited (NSE:SUPRIYA)

Market Cap	48.68B -9.3%
Revenue (ttm)	7.35B +9.7%
Net Income	1.85B +6.2%
EPS	23.04 +6.4%
Shares Out	80.48M
PE Ratio	26.25
Forward PE	20.58
Dividend	1.00 (0.17%)
Ex-Dividend Date	Sep 4, 2025

Volume	105,837
Average Volume	157,960
Open	590.00
Previous Close	580.85
Day's Range	585.80 - 606.95
52-Week Range	573.40 - 842.00
Beta	0.14
RSI	30.43
Earnings Date	Feb 9, 2026

About Supriya Lifescience

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti–hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 515
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SUPRIYA

Financial Performance

In fiscal year 2025, Supriya Lifescience's revenue was 6.96 billion, an increase of 22.12% compared to the previous year's 5.70 billion. Earnings were 1.88 billion, an increase of 57.80%.